Supplementary Appendix: Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial

Name: Supplementary Appendix: Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Creator: Andrew Blauvelt
Published: 2025-04-04T14:36:19.630Z
Keywords: Clinical Trial, Biologic Therapy, Psoriasis, Quality of Life, Safety Assessment, Efficacy Assessment

Blauvelt, Andrew; Langley, Richard G.; Lebwohl, Mark; Strober, Bruce; Warren, Richard; Puig, Lluis; Morita, Akimichi; Gordon, Kenneth B.; Fernandez-Peñas, Pablo; Kavanagh, Sarah; López Pinto, José M.; Lambert, Jérémy; Hoepken, Bengt; Deherder, Delphine; Cross, Nancy; Thaci, Diamant

doi:10.17632/24zjytjd7z.1

Supplementary Appendix: Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial

Published: 4 April 2025| Version 1 | DOI: 10.17632/24zjytjd7z.1

Contributors:

Andrew Blauvelt, Richard G. Langley, Mark Lebwohl, Bruce Strober, Richard Warren, Lluis Puig, Akimichi Morita, Kenneth B. Gordon, Pablo Fernandez-Peñas, Sarah Kavanagh, José M. López Pinto, Jérémy Lambert, Bengt Hoepken, Delphine Deherder, Nancy Cross, Diamant Thaci

Description

Supplementary materials for the BE BRIGHT 4-Year Efficacy and Safety manuscript, including Plain Language Summary and supplementary methods, tables, and figures.

Files

Funders

UCB Pharma (United States)
United States

Supplementary Appendix: Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial

Description

Files

Categories

Funders

Licence